Effects of propionyl-carnitine in patients with type 2 diabetes and peripheral vascular disease: results of a pilot trial. Ragozzino G, Mattera E, Madrid E, Salomone P, Fasano C, Gioia F, Acerra G, del Guercio R, Federico P. SourceDepartment of Internal Medicine, Clinical Methodology and Medical Angiology, Second University of Naples, Italy. giovanni.ragozzino@unina2.it Abstract OBJECTIVE: To assess the efficacy of propionyl-carnitine (PC) in patients with type 2 diabetes and peripheral arterial disease (PAD). PATIENTS AND METHODS: This was an open pharmacodynamic study. Twenty-four obese patients with type 2 diabetes and PAD (stage IIb) were enrolled in the study. After an initial run-in period of 7 days on a low-calorie diet (1600 +/- 150 kcal/day), patients received intravenous PC (600mg in 100mL saline solution Na/K 0.9%) twice daily for 10 days (T1). RESULTS: Treatment with PC produced statistically significant increases in maximal walking distance (30%; p < 0.05) and initial claudication distance (15%; p < 0.05) in 15 and eight patients, respectively. In addition, a decrease in dosage of oral antihyperglycaemic agents was observed in 21 patients at T1. No PC-related adverse effects were reported. CONCLUSIONS: This study showed that acute intravenous administration of PC in patients with type 2 diabetes with PAD improved PAD-related symptoms as well as glycaemic control.
Effects of Propionyl-Carnitine in Patients with type2 diabetes and peripheral vascular disease
MATTERA, Edi;
2004
Abstract
Effects of propionyl-carnitine in patients with type 2 diabetes and peripheral vascular disease: results of a pilot trial. Ragozzino G, Mattera E, Madrid E, Salomone P, Fasano C, Gioia F, Acerra G, del Guercio R, Federico P. SourceDepartment of Internal Medicine, Clinical Methodology and Medical Angiology, Second University of Naples, Italy. giovanni.ragozzino@unina2.it Abstract OBJECTIVE: To assess the efficacy of propionyl-carnitine (PC) in patients with type 2 diabetes and peripheral arterial disease (PAD). PATIENTS AND METHODS: This was an open pharmacodynamic study. Twenty-four obese patients with type 2 diabetes and PAD (stage IIb) were enrolled in the study. After an initial run-in period of 7 days on a low-calorie diet (1600 +/- 150 kcal/day), patients received intravenous PC (600mg in 100mL saline solution Na/K 0.9%) twice daily for 10 days (T1). RESULTS: Treatment with PC produced statistically significant increases in maximal walking distance (30%; p < 0.05) and initial claudication distance (15%; p < 0.05) in 15 and eight patients, respectively. In addition, a decrease in dosage of oral antihyperglycaemic agents was observed in 21 patients at T1. No PC-related adverse effects were reported. CONCLUSIONS: This study showed that acute intravenous administration of PC in patients with type 2 diabetes with PAD improved PAD-related symptoms as well as glycaemic control.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
